Central to the current discussion of anemia management with EPO and biosimilar drugs is the identification of those patients that respond normally to pharmacologic concentrations of EPO or erythropoiesis stimulating agents (ESAs) and those patients that do not. The gene discussed is EPO; the disease is anemia.